用于小儿急性肺损伤的表面活性剂
Surfactant for pediatric acute lung injury.
作者信息
Willson Douglas F, Chess Patricia R, Notter Robert H
机构信息
Pediatric ICU and Division of Pediatric Critical Care, University of Virginia Children's Medical Center, UVA Health Sciences System, Box 800386, Charlottesville, VA 22908-0386, USA.
出版信息
Pediatr Clin North Am. 2008 Jun;55(3):545-75, ix. doi: 10.1016/j.pcl.2008.02.016.
Abstract
This article reviews exogenous surfactant therapy and its use in mitigating acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) in infants, children, and adults. Biophysical and animal research documenting surfactant dysfunction in ALI/ARDS is described, and the scientific rationale for treatment with exogenous surfactant is discussed. Major emphasis is placed on reviewing clinical studies of surfactant therapy in pediatric and adult patients who have ALI/ARDS. Particular advantages from surfactant therapy in direct pulmonary forms of these syndromes are described. Also discussed are additional factors affecting the efficacy of exogenous surfactants in ALI/ARDS.
摘要
本文综述了外源性表面活性剂疗法及其在减轻婴儿、儿童和成人急性肺损伤（ALI）和急性呼吸窘迫综合征（ARDS）中的应用。文中描述了记录ALI/ARDS中表面活性剂功能障碍的生物物理和动物研究，并讨论了使用外源性表面活性剂治疗的科学依据。重点在于综述患有ALI/ARDS的儿科和成人患者的表面活性剂疗法临床研究。阐述了表面活性剂疗法在这些综合征直接肺损伤形式中的特殊优势。还讨论了影响外源性表面活性剂在ALI/ARDS中疗效的其他因素。
相似文献
1
Surfactant for pediatric acute lung injury.用于小儿急性肺损伤的表面活性剂
Pediatr Clin North Am. 2008 Jun;55(3):545-75, ix. doi: 10.1016/j.pcl.2008.02.016.
2
Surfactant therapy for acute lung injury and acute respiratory distress syndrome.表面活性物质治疗急性肺损伤和急性呼吸窘迫综合征。
Crit Care Clin. 2011 Jul;27(3):525-59. doi: 10.1016/j.ccc.2011.04.005.
3
[Exogenous surfactant preparations].[外源性表面活性剂制剂]
Pneumonol Alergol Pol. 1998;66(1-2):127-32.
4
Inactivation of pulmonary surfactant and the treatment of acute lung injuries.肺表面活性物质失活与急性肺损伤的治疗
Pediatr Pathol Mol Med. 2001 Nov-Dec;20(6):519-36.
5
A risk-benefit assessment of natural and synthetic exogenous surfactants in the management of neonatal respiratory distress syndrome.天然和合成外源性表面活性剂治疗新生儿呼吸窘迫综合征的风险效益评估
Drug Saf. 1998 May;18(5):321-37. doi: 10.2165/00002018-199818050-00002.
6
Mechanisms to explain surfactant responses.解释表面活性剂反应的机制。
Biol Neonate. 2006;89(4):298-302. doi: 10.1159/000092866. Epub 2006 Jun 1.
7
The future of exogenous surfactant therapy.外源性表面活性剂治疗的未来。
Respir Care. 2011 Sep;56(9):1369-86; discussion 1386-8. doi: 10.4187/respcare.01306.
8
Surfactant Components and Tracheal Aspirate Inflammatory Markers in Preterm Infants with Respiratory Distress Syndrome.表面活性物质成分和早产儿呼吸窘迫综合征患儿气管吸出物的炎症标志物。
J Pediatr. 2018 Dec;203:442-446. doi: 10.1016/j.jpeds.2018.08.019. Epub 2018 Sep 27.
9
Surfactant and the neonatal lung.表面活性剂与新生儿肺脏
Br J Hosp Med. 1997;58(8):381-4, 397.
10
Advances with surfactant.表面活性剂的进展。
Emerg Med Clin North Am. 2008 Nov;26(4):921-8, viii. doi: 10.1016/j.emc.2008.08.001.
引用本文的文献
1
Combination of pioglitazone, a PPARγ agonist, and synthetic surfactant B-YL prevents hyperoxia-induced lung injury in adult mice lung explants.吡格列酮联合过氧化物酶体增殖物激活受体γ激动剂和合成表面活性剂 B-YL 可预防成年小鼠肺组织体外高氧诱导的肺损伤。
Pulm Pharmacol Ther. 2023 Jun;80:102209. doi: 10.1016/j.pupt.2023.102209. Epub 2023 Mar 11.
2
Breath-Synchronized Nebulized Surfactant in a Porcine Model of Acute Respiratory Distress Syndrome.急性呼吸窘迫综合征猪模型中呼吸同步雾化表面活性剂的研究
Crit Care Explor. 2021 Feb 15;3(2):e0338. doi: 10.1097/CCE.0000000000000338. eCollection 2021 Feb.
3
Surfactant therapy for COVID-19 related ARDS: a retrospective case-control pilot study.COVID-19 相关 ARDS 的表面活性物质治疗：回顾性病例对照初步研究。
Respir Res. 2021 Jan 18;22(1):20. doi: 10.1186/s12931-020-01603-w.
4
Effect of low-dose exogenous surfactant on infants with acute respiratory distress syndrome after cardiac surgery: a retrospective analysis.心脏手术后急性呼吸窘迫综合征婴儿应用小剂量外源性表面活性剂的效果：回顾性分析。
BMC Pulm Med. 2020 Aug 6;20(1):210. doi: 10.1186/s12890-020-01251-2.
5
The Use of Exogenous Lung Surfactant (Poractant Alfa) in Acute Respiratory Failure by Drowning.外源性肺表面活性物质（固尔苏）在溺水所致急性呼吸衰竭中的应用
Case Rep Crit Care. 2020 Jun 6;2020:9270791. doi: 10.1155/2020/9270791. eCollection 2020.
6
Activation of Invariant Natural Killer T Cells Redirects the Inflammatory Response in Neonatal Sepsis.固有自然杀伤 T 细胞的激活可重新定向新生儿败血症中的炎症反应。
Front Immunol. 2018 Apr 23;9:833. doi: 10.3389/fimmu.2018.00833. eCollection 2018.
7
Surfactants in Acute Respiratory Distress Syndrome in Infants and Children: Past, Present and Future.婴幼儿及儿童急性呼吸窘迫综合征中的表面活性剂：过去、现在与未来
Clin Drug Investig. 2017 Aug;37(8):729-736. doi: 10.1007/s40261-017-0532-1.
8
Design of Surfactant Protein B Peptide Mimics Based on the Saposin Fold for Synthetic Lung Surfactants.基于鞘脂激活蛋白折叠结构设计用于合成肺表面活性剂的表面活性蛋白B肽模拟物
Biomed Hub. 2016 Sep-Dec;1(3):1-21. doi: 10.1159/000451076. Epub 2016 Nov 16.
9
Regulation of p53-mediated changes in the uPA-fibrinolytic system and in lung injury by loss of surfactant protein C expression in alveolar epithelial cells.肺泡上皮细胞表面活性蛋白C表达缺失对p53介导的尿激酶型纤溶酶原激活物-纤维蛋白溶解系统变化及肺损伤的调控作用
Am J Physiol Lung Cell Mol Physiol. 2017 Jun 1;312(6):L783-L796. doi: 10.1152/ajplung.00291.2016. Epub 2017 Apr 6.
10
Pediatric Acute Respiratory Distress Syndrome: Fibrosis versus Repair.儿童急性呼吸窘迫综合征：纤维化与修复。
Front Pediatr. 2016 Mar 30;4:28. doi: 10.3389/fped.2016.00028. eCollection 2016.
本文引用的文献
1
Dynamic surface activity of a fully synthetic phospholipase-resistant lipid/peptide lung surfactant.一种完全合成的抗磷脂酶脂质/肽肺表面活性剂的动态表面活性
PLoS One. 2007 Oct 17;2(10):e1039. doi: 10.1371/journal.pone.0001039.
2
Novel phospholipase-resistant lipid/peptide synthetic lung surfactants.新型抗磷脂酶脂质/肽合成肺表面活性剂。
Mini Rev Med Chem. 2007 Sep;7(9):932-44. doi: 10.2174/138955707781662627.
3
Hydrophobic surfactant proteins and their analogues.疏水表面活性蛋白及其类似物。
Neonatology. 2007;91(4):303-10. doi: 10.1159/000101346. Epub 2007 Jun 7.
4
Activity and inhibition resistance of a phospholipase-resistant synthetic surfactant in rat lungs.一种抗磷脂酶的合成表面活性剂在大鼠肺中的活性及抗抑制性
Am J Respir Cell Mol Biol. 2007 Oct;37(4):387-94. doi: 10.1165/rcmb.2006-0434OC. Epub 2007 Jun 7.
5
Acute lung injury in pediatric intensive care in Australia and New Zealand: a prospective, multicenter, observational study.澳大利亚和新西兰儿科重症监护中的急性肺损伤：一项前瞻性、多中心观察性研究。
Pediatr Crit Care Med. 2007 Jul;8(4):317-23. doi: 10.1097/01.PCC.0000269408.64179.FF.
6
Surfactant dysfunction and lung injury due to the E. coli virulence factor hemolysin in a rat pneumonia model.在大鼠肺炎模型中，大肠杆菌毒力因子溶血素导致的表面活性剂功能障碍和肺损伤。
Am J Physiol Lung Cell Mol Physiol. 2007 Mar;292(3):L632-43. doi: 10.1152/ajplung.00326.2006.
7
Synthesis and surface activity of diether-linked phosphoglycerols: potential applications for exogenous lung surfactants.二醚连接的磷酸甘油的合成及其表面活性：在外源性肺表面活性剂中的潜在应用
Bioorg Med Chem Lett. 2007 Jan 1;17(1):113-7. doi: 10.1016/j.bmcl.2006.09.083. Epub 2006 Sep 30.
8
Pneumocystis carinii infection sensitizes lung to radiation-induced injury after syngeneic marrow transplantation: role of CD4+ T cells.卡氏肺孢子虫感染使同基因骨髓移植后肺对辐射诱导的损伤敏感：CD4+T细胞的作用
Am J Physiol Lung Cell Mol Physiol. 2006 Jun;290(6):L1087-96. doi: 10.1152/ajplung.00441.2005. Epub 2006 Jan 6.
9
The role of charged amphipathic helices in the structure and function of surfactant protein B.带电荷的两亲性螺旋在表面活性蛋白B的结构和功能中的作用
J Pept Res. 2005 Dec;66(6):364-74. doi: 10.1111/j.1399-3011.2005.00300.x.
10
Incidence of acute respiratory distress syndrome and its relation to age.急性呼吸窘迫综合征的发病率及其与年龄的关系。
J Crit Care. 2005 Sep;20(3):274-80. doi: 10.1016/j.jcrc.2005.05.008.
Zotero 插件